IP Library Granted Patent US 9,012,213
Granted Patent B2
US 9,012,213 · App. 12/632,985 · Granted Apr 21, 2015

Bacteria mediated gene silencing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,213
App. No.
12/632,985
Granted
Apr 21, 2015
Kind
B2
Abstract

Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

Claims (23)

1. A plasmid comprising a prokaryotic promoter and one or more DNA molecules, wherein the prokaryotic promoter comprises the promoter sequence of SEQ ID NO: 378, and the one or more DNA molecules encode for one or more short hairpin RNAs (shRNAs).

2. The plasmid of claim 1 further comprising terminator sequences.

3. The plasmid of claim 1 further comprising a rrnC terminator.

4. The plasmid of claim 1 further comprising invasion factor sequences.

5. The plasmid of claim 1 further comprising an Inv gene.

6. The plasmid of claim 1 further comprising lysis regulation sequences.

7. The plasmid of claim 1 further comprising a HylA gene.

8. The plasmid of claim 1 , wherein the target gene for the one or more shRNAs is selected from the group consisting of RAS, β-catenin, one or more HPV oncogenes, APC, HER-2, MDR-1, MRP-2, FATP4, SGLUT-1, GLUT-2, GLUT-5, APOBEC-1, MTP, IL-6, IL-6R, IL-7, IL-12, IL-13, IL-13 Ra-1, IL-18, p38/JNK MAP Kinase, p65/NF-κB, CCL20 (or MIP-3α), Claudin-2, Chitinase 3-like 1, APOA-IV, MHC class I and MHC class II.

9. The plasmid of claim 1 , wherein the target sequence for the one or more shRNA's is selected from the group consisting of SEQ ID NOs: 52-377.

10. The plasmid of claim 1 , wherein the nucleotide sequence of the plasmid is SEQ ID NO:560.

11. A bacterium comprising a plasmid comprising a prokaryotic promoter and one or more DNA molecules, wherein the prokaryotic promoter comprises the promoter sequence of SEQ ID NO: 378, and the one or more DNA molecules encode for one or more short hairpin RNAs (shRNAs).

12. The bacterium of claim 11 , wherein the bacterium is a non-pathogenic or non-virulent bacterium.

13. The bacterium of claim 11 , wherein the bacterium is an invasive bacterium.

14. The bacterium of claim 11 , wherein the bacterium is attenuated.

15. The bacterium of claim 11 , wherein the nucleotide sequence of the plasmid is SEQ ID NO:560.

16. The bacterium of claim 11 , wherein the target gene for the one or more shRNAs is selected from the group consisting of RAS, β-catenin, one or more HPV oncogenes, APC, HER-2, MDR-1, MRP-2, FATP4, SGLUT-1, GLUT-2, GLUT-5, APOBEC-1, MTP, IL-6, IL-6R, IL-7, IL-12, IL-13, IL-13 Ra-1, IL-18, p38/JNK MAP Kinase, p65/NF-κB, CCL20 (or MIP-3α), Claudin-2, Chitinase 3-like 1, APOA-IV, MHC class I and MHC class II.

17. The bacterium of claim 11 , wherein the target sequence for the one or more shRNA's is selected from the group consisting of SEQ ID NOs: 52-377.

18. A composition comprising the bacterium of claim 11 and a pharmaceutically acceptable carrier.

19. A eukaryotic cell comprising a plasmid comprising a prokaryotic promoter and one or more DNA molecules, wherein the prokaryotic promoter comprises the promoter sequence of SEQ ID NO: 378, and the one or more DNA molecules encode for one or more short hairpin RNAs (shRNAs).

20. The eukaryotic cell of claim 19 , wherein the eukaryotic cell is an animal cell or plant cell.

21. The eukaryotic cell of claim 19 , wherein the eukaryotic cell is a human cell.

22. The eukaryotic cell of claim 19 , wherein the eukaryotic cell is selected from the group consisting of gastrointestinal epithelial cells, macrophages, cervical epithelial cells, rectal epithelial cells and pharyngeal epithelial cells.

23. The eukaryotic cell of claim 19 , wherein the eukaryotic cell is selected from the group consisting of a cervical epithelial cell, a rectal epithelial cell, a macrophage, a skin cell, a melanocyte, a keratinocyte, a hair follicle cell, colon cancer cell, an ovarian cancer cell, a bladder cancer cell, a pharyngeal cancer cell, a rectal cancer cell, a prostate cancer cell, a breast cancer cell, a lung cancer cell, a renal cancer cell, a pancreatic cancer cell, and a hematologic cancer cell.

Assignments (7)
SECURITY INTEREST Recorded Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →
MERGER Recorded Mar 15, 2015
From: CEQUENT PHARMACEUTICALS, INC.
To: MDRNA, INC.
Reel/Frame 035167/0931 →
CHANGE OF NAME Recorded Mar 15, 2015
From: MDRNA, INC.
To: MARINA BIOTECH, INC.
Reel/Frame 035204/0245 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded May 13, 2013
From: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: MONSANTO COMPANY
Reel/Frame 030401/0461 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2009
From: FRUEHAUF, JOHANNES; VAZE, MORESHWAR BHANUDAS; LAROUX, FLOYD STEPHEN, JR.; SAUER, NOEL JOY
To: CEQUENT PHARMACEUTICALS, INC.
Reel/Frame 023618/0347 →